The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

This was the stock's second consecutive day of losses.

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound. Shares ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

Genetic testing firm 23andMe has been fined £2.31 million by the UK's data protection watchdog for "serious security failings ...

AndMe had “inadequate” security systems and was “slow to respond” to warning signs customers’ sensitive data was at risk before the "profoundly damaging" hack, officials say.

DNA firm 23andMe fined £2.31m by UK regulator for a 2023 data breach that exposed sensitive health and family information. Sale to TTAM Research to include stricter privacy commitments.

Regeneron Pharmaceuticals had previously agreed to acquire the company for $256 million. TTAM’s higher bid and added consumer protections ultimately led the board’s special committee to select it as ...